Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3-Mutated Gliomas - (INTERCEPT-H3)

NCT04808245 is registered in ClinicalTrials.gov with German Cancer Research Center as lead sponsor.

NCT NCT04808245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04808245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3-Mutated Gliomas - (INTERCEPT-H3)
Lead sponsor
German Cancer Research Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 15, 2023
Completion date
November 30, 2026
Enrollment
15 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed h3-mutated glioma